Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) EBT (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of EBT data on record, last reported at -$2.9 million in Q3 2025.

  • For Q3 2025, EBT fell 58.5% year-over-year to -$2.9 million; the TTM value through Sep 2025 reached -$13.7 million, down 17.6%, while the annual FY2024 figure was -$10.9 million, 48.85% up from the prior year.
  • EBT reached -$2.9 million in Q3 2025 per COEP's latest filing, up from -$4.3 million in the prior quarter.
  • Across five years, EBT topped out at -$100001.0 in Q3 2021 and bottomed at -$19.2 million in Q1 2022.
  • Average EBT over 5 years is -$5.0 million, with a median of -$3.2 million recorded in 2023.
  • The widest YoY moves for EBT: up 78.43% in 2022, down 13634.12% in 2022.
  • A 5-year view of EBT shows it stood at -$13.6 million in 2021, then soared by 78.43% to -$2.9 million in 2022, then fell by 27.61% to -$3.8 million in 2023, then increased by 19.81% to -$3.0 million in 2024, then rose by 3.75% to -$2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$2.9 million in Q3 2025, -$4.3 million in Q2 2025, and -$3.4 million in Q1 2025.